Replies to post #184132 on Biotech Values

[masterlongevity]

$rna Congrats to iwfal

[ghmm]

RNA / BMRN:

Did anyone else (besides me) find it interesting that BMRN acquired all of RNA rather then work out some sort of licensing deal? From the call it was pretty clear that BMRN's interest at this time was only in acquiring Drisapersen.

[DewDiligence]

BMRN sells 9.78M* shares @$93.25—a 3% discount to yesterday’s close:

http://finance.yahoo.com/news/biomarin-announces-pricing-public-offering-054022453.html

This offering will raise about $855M* in net proceeds, which is sufficient to pay for the RNA acquisition in the most expensive scenario where Proensa is approved by the FDA/EMA quickly (#msg-108456369).

*Assuming exercise of underwriter’s option.